Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Maintenance in Extensive Small Cell Lung Cancer
NCT03983759Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2019
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in small cell lung cancer (SCLC), sponsored by Henan Cancer Hospital. Primary endpoint: Median Survival Time at 2 years. Status: unknown.
02
Drugs
sintilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03983759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03983759.